Payment overview · 2025
General Payments
$141.31
7 reported records · 4 companies
Healthcare provider profile · identity verified
Ricky Kellenberger, D.O
Allopathic & Osteopathic Physicians|Emergency Medicine · FORT SCOTT, KS · NPI 1700864568
Verified facts
What the public records show
CMS Open Payments records show Ricky Kellenberger, D.O received $141.31 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.74 | 52.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.13 | 17.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $21.72 | 15.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.72 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.31 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 84 |
| Montelukast Sodium | Montelukast Sodium | 356 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 352 | 54 |
| Lisinopril | Lisinopril | 347 | 84 |
| Furosemide | Furosemide | 340 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 66 |
| Losartan Potassium | Losartan Potassium | 303 | 69 |
| Gabapentin | Gabapentin | 293 | 63 |
| Simvastatin | Simvastatin | 256 | 55 |
| Omeprazole | Omeprazole | 240 | 45 |
| Potassium Chloride | Potassium Chloride | 234 | 43 |
| Ezetimibe | Ezetimibe | 214 | 52 |
| Metformin Hcl | Metformin Hcl | 199 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 198 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 186 | 30 |
| Meloxicam | Meloxicam | 182 | 45 |
| Eliquis | Apixaban | 177 | 32 |
| Clonazepam | Clonazepam | 154 | 23 |
| Trazodone Hcl | Trazodone Hcl | 147 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 32 |
| Prednisone | Prednisone | 141 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 131 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 37 |
| Alprazolam | Alprazolam | 125 | 24 |
| Glipizide | Glipizide | 120 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 118 | 21 |
| Spironolactone | Spironolactone | 114 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 37 |
| Pregabalin | Pregabalin | 106 | 15 |
| Carvedilol | Carvedilol | 98 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 16 |
| Famotidine | Famotidine | 95 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 91 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 23 |
| Tramadol Hcl | Tramadol Hcl | 87 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 29 |
| Buprenorphine | Buprenorphine | 81 | 15 |
| Celecoxib | Celecoxib | 80 | 17 |
| Baclofen | Baclofen | 78 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 78 | 12 |
| Allopurinol | Allopurinol | 75 | 17 |
| Estradiol | Estradiol | 75 | 13 |
| Bupropion Hcl | Bupropion Hcl | 73 | 15 |
| Farxiga | Dapagliflozin Propanediol | 72 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 21 |
| Propranolol Hcl | Propranolol Hcl | 68 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 13 |
| Buspirone Hcl | Buspirone Hcl | 66 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 66 | 32 |
| Ozempic | Semaglutide | 66 | 16 |
| Sertraline Hcl | Sertraline Hcl | 66 | 11 |
| Donepezil Hcl | Donepezil Hcl | 64 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 61 | 11 |
| Fluconazole | Fluconazole | 60 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 60 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 11 |
| Ibuprofen | Ibuprofen | 59 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | suppressed |
| Methotrexate | Methotrexate Sodium | 58 | 14 |
| Topiramate | Topiramate | 58 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | suppressed |
| Finasteride | Finasteride | 56 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 53 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 53 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Linzess | Linaclotide | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 48 | 14 |
| Nystatin | Nystatin | 48 | 24 |
| Risperidone | Risperidone | 48 | suppressed |
| Fenofibrate | Fenofibrate | 47 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Acyclovir | Acyclovir | 41 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Cefdinir | Cefdinir | 29 | 22 |
| Diazepam | Diazepam | 29 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Olanzapine | Olanzapine | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 19 | suppressed |
| Piroxicam | Piroxicam | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amoxapine | Amoxapine | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.31 · 7 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FABRAZYME, FANAPT, FARXIGA, HETLIOZ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error